Rigel Pharmaceuticals Inc RIGL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:18 PM EDT
0.98UNCH (UNCH)
Volume
51,083
Close
0.9822quote price arrow down-0.0022 (-0.2235%)
Volume
656,475
52 week range
0.71 - 1.96
Loading...
  • Open1.00
  • Day High1.01
  • Day Low0.9519
  • Prev Close0.9844
  • 52 Week High1.96
  • 52 Week High Date05/18/23
  • 52 Week Low0.71
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap172.283M
  • Shares Out175.40M
  • 10 Day Average Volume1.29M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change-32.26

KEY STATS

  • Open1.00
  • Day High1.01
  • Day Low0.9519
  • Prev Close0.9844
  • 52 Week High1.96
  • 52 Week High Date05/18/23
  • 52 Week Low0.71
  • 52 Week Low Date10/25/23
  • Market Cap172.283M
  • Shares Out175.40M
  • 10 Day Average Volume1.29M
  • Dividend-
  • Dividend Yield-
  • Beta1.05
  • YTD % Change-32.26

RATIOS/PROFITABILITY

  • EPS (TTM)-0.11
  • P/E (TTM)-8.65
  • Fwd P/E (NTM)-14.23
  • EBITDA (TTM)-13.451M
  • ROE (TTM)-699.05%
  • Revenue (TTM)120.346M
  • Gross Margin (TTM)93.22%
  • Net Margin (TTM)-16.45%
  • Debt To Equity (MRQ)-188.47%

EVENTS

  • Earnings Date07/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Rigel Pharmaceuticals Inc

 

Content From Our Affiliates

Profile

MORE
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with...
Gregg Lapointe CPA
Independent Chairman of the Board
Raul Rodriguez
President, Chief Executive Officer, Director
Dean Schorno CPA
Chief Financial Officer, Executive Vice President
Raymond Furey
Executive Vice President, General Counsel, Company Secretary
Lisa Rojkjaer M.D.
Executive Vice President, Chief Medical Officer
Address
611 GATEWAY BOULEVARD, SUITE 900
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
MCRB
Seres Therapeutics Inc
0.9651-0.0549-5.3824%
CTMX
CytomX Therapeutics Inc
1.89-0.09-4.55%
HBIO
Harvard Bioscience Inc
3.39-0.14-3.97%
RPTX
Repare Therapeutics Inc
3.70+0.20+5.71%
KPTI
Karyopharm Therapeutics Inc
1.12+0.03+2.75%